TY - JOUR
T1 - Mirna levels as a biomarker for anti-vegf response in patients with diabetic macular edema
AU - Vader, Maartje J. C.
AU - Habani, Yasmin I.
AU - Schlingemann, Reinier O.
AU - Klaassen, Ingeborg
AU - Vader, Madeleine J. C.
N1 - Funding Information: This research was funded by ZonMw, The Netherlands, Organisation for Health Research and Development Grant 171202019 and the following foundations: Landelijke Stichting voor Blinden en Slechtzienden, Algemene Nederlandse Vereniging Ter Voorkoming Van Blindheid, Sticht-ing Blindenpenning, Stichting Oogfonds Nederland, which contributed through UitZicht (Grant UitZicht2016-31). Other grants were provided by Rotterdamse Stichting Blindenbelangen (Grant B20160059), Stichting Ooglijders, Stichting tot Verbetering van het Lot der Blinden, Stichting Blin-denhulp. This study was published with the help of the Edward en Marianne Blaauw Fonds voor Oogheelkunde (Edward and Marianne Blaauw Fund for Ophthalmology). Funding Information: Funding: This research was funded by ZonMw, The Netherlands, Organisation for Health Research and Development Grant 171202019 and the following foundations: Landelijke Stichting voor Blinden en Slechtzienden, Algemene Nederlandse Vereniging Ter Voorkoming Van Blindheid, Sticht-ing Blindenpenning, Stichting Oogfonds Nederland, which contributed through UitZicht (Grant UitZicht2016-31). Other grants were provided by Rotterdamse Stichting Blindenbelangen (Grant B20160059), Stichting Ooglijders, Stichting tot Verbetering van het Lot der Blinden, Stichting Blin-denhulp. This study was published with the help of the Edward en Marianne Blaauw Fonds voor Oogheelkunde (Edward and Marianne Blaauw Fund for Ophthalmology). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at baseline from 135 patients who were included in the BRDME study, a randomized controlled comparative trial of monthly bevacizumab or ranibizumab treatment for 6 months in patients with diabetic macular edema (Trialregister.nl, NTR3247). Best corrected visual acuity letter score (BCVA) and retinal central area thickness (CAT) were measured monthly during the 6-month follow-up. Levels of selected miRNAs were quantified. Results: Following linear regression analysis, the levels of four miRNAs were negatively associated with baseline CAT. Multivariable regression analysis confirmed this association for miR-181a. No associations with changes in CAT after 3 or 6 months of anti-VEGF treatment were found. In addition, no associations with miRNA levels with baseline BCVA or change in BCVA after 3 or 6 months of anti-VEGF treatment were found. Conclusions: Circulating miR-181a levels were negatively associated with CAT at baseline. However, no associations between miRNA levels and the response to anti-VEGF therapy were found.
AB - Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at baseline from 135 patients who were included in the BRDME study, a randomized controlled comparative trial of monthly bevacizumab or ranibizumab treatment for 6 months in patients with diabetic macular edema (Trialregister.nl, NTR3247). Best corrected visual acuity letter score (BCVA) and retinal central area thickness (CAT) were measured monthly during the 6-month follow-up. Levels of selected miRNAs were quantified. Results: Following linear regression analysis, the levels of four miRNAs were negatively associated with baseline CAT. Multivariable regression analysis confirmed this association for miR-181a. No associations with changes in CAT after 3 or 6 months of anti-VEGF treatment were found. In addition, no associations with miRNA levels with baseline BCVA or change in BCVA after 3 or 6 months of anti-VEGF treatment were found. Conclusions: Circulating miR-181a levels were negatively associated with CAT at baseline. However, no associations between miRNA levels and the response to anti-VEGF therapy were found.
KW - Anti-VEGF
KW - Biomarker
KW - Central area thickness
KW - Diabetic macular edema
KW - MicroRNA
KW - Visual acuity
UR - http://www.scopus.com/inward/record.url?scp=85121638443&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85121638443&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34945769
U2 - https://doi.org/10.3390/jpm11121297
DO - https://doi.org/10.3390/jpm11121297
M3 - Article
C2 - 34945769
SN - 2075-4426
VL - 11
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 12
M1 - 1297
ER -